查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1532562

肉瘤藥物市場 - 按疾病適應症（軟組織、骨）、治療（化療、標靶治療、免疫療法）、藥物類型（品牌、學名藥）、配銷通路（醫院、零售和線上藥局） - 全球預測（2024 - 2032） ）

Sarcoma Drugs Market - By Disease Indication (Soft Tissue, Bone), Treatment (Chemotherapy, Targeted Therapy, Immunotherapy), Drug Type (Branded, Generic), Distribution Channel (Hospital, Retail, & Online Pharmacy) - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 220 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於臨床試驗和研究進展的激增，2024 年至 2032 年全球肉瘤藥物市場的複合年成長率將達到 8.5%。肉瘤是一種起源於結締組織的罕見癌症，需要專門的治療，因此需要大量投資來開發有效的療法。臨床試驗的增加對於發現新候選藥物和最佳化現有治療方法至關重要，從而改善患者的治療結果。例如，2023年10月，一項臨床試驗證實了atezolizumab（Tecentriq）治療一種罕見類型肉瘤的有效性。這項研究發表在《新英格蘭醫學雜誌》上，對 52 名晚期腺泡軟組織肉瘤患者的免疫療法藥物進行了評估。

研究重點是標靶療法、免疫療法和個人化醫療，這為更有效、毒性更低的治療帶來了希望。了解肉瘤生物學和基因譜的創新也透過開發客製化的治療方案來推動市場成長。隨著製藥公司和研究機構不斷探索新的藥物配方和治療策略，對肉瘤藥物的需求預計將上升，反映出對推進癌症治療和解決該領域未滿足的醫療需求的更廣泛承諾。

整個肉瘤藥物產業根據疾病適應症、治療方法、藥物類型、配銷通路和地區進行分類。

根據疾病適應症，骨肉瘤領域的肉瘤藥物市場收入將在2024年至2032年實現令人稱讚的複合年成長率。和抗藥性，需要專門的藥物治療。研究和臨床試驗的進步正在推動藥物開發的創新，重點是標靶治療和個人化醫療。隨著對骨肉瘤認知的提高和新的治療選擇的出現，肉瘤藥物的市場正在擴大，以滿足患者未滿足的需求並提高治療效果。

在治療方面，從2024年到2032年，標靶治療領域將出現可觀的成長。選擇。這些創新藥物旨在最大限度地減少對健康組織的損害，同時增強對癌細胞的破壞，從而改善患者的治療效果並減少副作用。隨著研究不斷揭示各種肉瘤類型的分子基礎，標靶治療的開發和採用正在加速。這一趨勢正在推動肉瘤藥物市場的投資和興趣增加，反映出朝向更個人化和有效的癌症治療的轉變。

2024年至2032年，歐洲肉瘤藥物市場將呈現顯著的複合年成長率。隨著醫療保健提供者和患者尋求更有效和量身定做的選擇，對包括標靶治療和免疫療法在內的創新療法的需求不斷成長。此外，歐洲嚴格的監管框架和對臨床試驗的高度重視正在加速新肉瘤藥物的開發和批准，進一步推動該地區的市場需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 肉瘤發生率增加
      • 研究與開發的進步
      • 意識和早期發現舉措
    • 產業陷阱與挑戰
      • 開發成本高
      • 不良反應和毒性
  • 成長潛力分析
  • 技術景觀
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按疾病適應症，2021 - 2032 年

  • 主要趨勢
  • 軟組織肉瘤
    • 平滑肌肉瘤
    • 脂肪肉瘤
    • 滑膜肉瘤
    • 纖維肉瘤
    • 血管肉瘤
    • 上皮樣肉瘤
    • 卡波西氏肉瘤
    • 其他軟組織肉瘤
  • 骨肉瘤
    • 骨肉瘤
    • 尤文氏肉瘤
    • 軟骨肉瘤

第 6 章：市場估計與預測：按處理方式，2021 - 2032 年

  • 主要趨勢
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他治療

第 7 章：市場估計與預測：按藥物類型，2021 - 2032

  • 主要趨勢
  • 品牌化
  • 通用的

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Abbott laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lupin Limited
  • MERCK & CO., INC.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
簡介目錄
Product Code: 9617

Global Sarcoma Drugs Market will witness 8.5% CAGR between 2024 and 2032 due to a surge in clinical trials and research advancements. Sarcoma, a rare group of cancers originating in connective tissues, requires specialized treatments, prompting significant investment in developing effective therapies. The rise in clinical trials is crucial for discovering new drug candidates and optimizing existing treatments, leading to improved outcomes for patients. For instance, in October 2023, A clinical trial confirmed the effectiveness of atezolizumab (Tecentriq) in treating a rare type of sarcoma. The study, published in the New England Journal of Medicine, evaluated the immunotherapy drug on 52 patients with advanced alveolar soft part sarcoma.

Research is focusing on targeted therapies, immunotherapies, and personalized medicine, which offer hope for more effective and less toxic treatments. Innovations in understanding sarcoma biology and genetic profiling are also driving market growth by enabling the development of tailored therapeutic options. As pharmaceutical companies and research institutions continue to explore novel drug formulations and therapeutic strategies, the demand for sarcoma drugs is expected to rise, reflecting a broader commitment to advancing cancer care and addressing unmet medical needs in the field.

The overall Sarcoma Drugs Industry is classified based on the disease indication, treatment, drug type, distribution channel, and region.

Based on disease indication, the sarcoma drugs market revenue from the bone sarcoma segment will register a commendable CAGR from 2024 to 2032. Bone sarcoma, including types such as osteosarcoma and Ewing's sarcoma, requires specialized drug therapies due to its unique biological characteristics and resistance to standard treatments. Advances in research and clinical trials are driving innovation in drug development, focusing on targeted therapies and personalized medicine. As the understanding of bone sarcoma improves and new therapeutic options emerge, the market for sarcoma drugs is expanding to address the unmet needs of patients and enhance treatment outcomes.

In terms of treatment, the targeted therapy segment will witness an appreciable growth from 2024 to 2032. Targeted therapies, which aim at specific genetic mutations or molecular pathways involved in sarcoma, offer more precise and effective treatment options compared to traditional therapies. These innovative drugs are designed to minimize damage to healthy tissues while enhancing the destruction of cancer cells, leading to improved patient outcomes and reduced side effects. As research continues to uncover the molecular underpinnings of various sarcoma types, the development and adoption of targeted therapies are accelerating. This trend is driving increased investment and interest in the sarcoma drugs market, reflecting a shift towards more personalized and effective cancer treatment.

Europe sarcoma drugs market will exhibit a notable CAGR from 2024 to 2032. European countries are prioritizing advanced treatments and personalized medicine to address the unique challenges of sarcoma, a rare and complex group of cancers. The demand for innovative therapies, including targeted treatments and immunotherapies, is growing as healthcare providers and patients seek more effective and tailored options. Additionally, stringent regulatory frameworks and a strong emphasis on clinical trials in Europe are accelerating the development and approval of new sarcoma drugs, further boosting market demand across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of sarcomas
      • 3.2.1.2 Advancements in research and development
      • 3.2.1.3 Awareness and early detection initiatives
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High development costs
      • 3.2.2.2 Adverse effects and toxicity
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Disease Indication, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Soft tissue sarcoma
    • 5.2.1 Leiomyosarcoma
    • 5.2.2 Liposarcoma
    • 5.2.3 Synovial sarcoma
    • 5.2.4 Fibrosarcoma
    • 5.2.5 Angiosarcoma
    • 5.2.6 Epithelioid sarcoma
    • 5.2.7 Kaposi's sarcoma
    • 5.2.8 Other soft tissue sarcomas
  • 5.3 Bone sarcoma
    • 5.3.1 Osteosarcoma
    • 5.3.2 Ewing sarcoma
    • 5.3.3 Chondrosarcoma

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Chemotherapy
  • 6.3 Targeted therapy
  • 6.4 Immunotherapy
  • 6.5 Other treatments

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Branded
  • 7.3 Generic

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacy
  • 8.3 Retail pharmacy
  • 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott laboratories
  • 10.2 AbbVie Inc.
  • 10.3 Amneal Pharmaceuticals Inc.
  • 10.4 Bausch Health Companies Inc.
  • 10.5 Bayer AG
  • 10.6 Baxter International Inc.
  • 10.7 Bristol-Myers Squibb Company
  • 10.8 GSK plc
  • 10.9 Hikma Pharmaceuticals PLC
  • 10.10 Johnson & Johnson
  • 10.11 Lupin Limited
  • 10.12 MERCK & CO., INC.
  • 10.13 Novartis AG
  • 10.14 Pfizer Inc.
  • 10.15 Sun Pharmaceutical Industries Ltd